Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
mesoblast將提交FDA申請，以治療兒童GVHD的Ryoncil
Mesoblast Limited (NASDAQ:MESO, ASX:MSB))))), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week.
全球領先的異基因細胞藥物治療炎症性疾病公司Mesoblast Limited（納斯達克股票代碼:MESO，澳大利亞證券交易所股票代碼:MSB))))))證實，它將在下週向美國食品和藥品管理局(FDA)提交其生物製品許可申請 (BLA)，以獲得批准用於治療類固醇難治性急性移植物抗宿主病（SR-aGVHD）患兒的Ryoncil（remestemcel-L） 。